Scarica l'app Stockscreener
30.34
2.78%
0.82
Dopo l'orario di chiusura:
30.34
Precedente Chiudi:
$29.52
Aprire:
$29.89
Volume 24 ore:
1.06M
Relative Volume:
0.83
Capitalizzazione di mercato:
$3.86B
Reddito:
$236.00M
Utile/perdita netta:
$-369.00M
Rapporto P/E:
-9.5325
EPS:
-3.1828
Flusso di cassa netto:
$-489.00M
1 W Prestazione:
+2.92%
1M Prestazione:
+2.92%
6M Prestazione:
+59.77%
1 anno Prestazione:
+189.50%
Intervallo 1D:
$29.74
$30.56
Intervallo di 1 settimana:
$28.92
$31.28
Portata 52W:
$10.07
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
30.34 | 3.76B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - PR Newswire
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum BuildsEMA Signal - vinanet.vn
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain? - Sahm
Arcus Biosciences (RCUS) Gains Nearly 2% as Shares Trade Near Key Resistance at $30.90Call Dominated - vinanet.vn
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - The Globe and Mail
(RCUS) Volatility Zones as Tactical Triggers - Stock Traders Daily
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $29 - Moomoo
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating - Yahoo Finance
HC Wainwright Issues Optimistic Forecast for RCUS Earnings - MarketBeat
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Arcus Biosciences Q2 Earnings Call Highlights - MarketBeat
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45 - moomoo.com
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead - Stock Titan
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD) - The Globe and Mail
Arcus Biosciences Inc (RCUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Wells Fargo -- Price Target Raised to $26.00 - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00 - MarketBeat
RCUS Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside - TradingView
Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating - Yahoo Finance
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates - Stocktwits
RCUS Looks 129.7% Overvalued on GF Value™ - GuruFocus
RCUS SWOT Analysis: Financial Struggles and Competitive Pressures Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Arcus Biosciences tops Q2 2026 estimates, shares rise - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Arcus Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:RCUS) 2026-08-05 - Seeking Alpha
Arcus Q2 2026 slides: casdatifan leads oncology, immunology push - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
RCUS: Casdatifan advances as a potential RCC backbone therapy, supported by robust cash and key data ahead - TradingView
Arcus Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M - marketscreener.com
Arcus Biosciences Q2 revenue falls sharply on lower license income - TradingView
Arcus Biosciences 2Q 2026: Revenue $41M, EPS ($0.72) — 10-Q Summary - TradingView
RCUS: Advanced casdatifan in ccRCC, secured new partnerships, and maintained strong cash runway - TradingView
Arcus Biosciences reports Q2 2026 results: $41M revenue, $775M cash, $91M net loss - TradingView
Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options - Stock Titan
Arcus Biosciences, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Arcus Biosciences earnings in focus as kidney cancer drug advances By Investing.com - Investing.com Nigeria
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):